Falk Gastro Info 3/2015

Video

 

Video course abdominal ultrasound

Intrahepatic bile ducts

 

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

©2015 Falk Foundation e.V., Freiburg. All rights reserved.

 

 

Please switch on your loudspeakers!

 

 

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=140&L=1

 

 

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/24_Gall_Intrahepatic_bile_ducts_ENG.mp4

 

 

Preview images:

 

180 x 109 pixels

http://www.drfalkpharma.de/fileadmin/media/Video/Sono_Galle_Clip24_180P.jpg

 

580 x 350 pixels

http://www.drfalkpharma.de/fileadmin/media/Video/Sono_Galle_Clip24_580.jpg

 

 

 

 

Bowel

 

 

Text:

Dignass A et al, J Crohns Colitis. 2014;8(9):970–80

In mild-to-moderately active Crohn’s disease Budesonide 9 mg once daily is as effective and safe as 3 mg TID.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#28270

 

Text:

Kariyawasam VC et al, Inflamm Bowel Dis. 2014;20(8):1382–90

Early immunomodulator use with thiopurines or methotrexate is significantly associated with the reduced need for abdominal and perianal surgery in Crohn’s disease.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28271

 

 

Text:

Amiot A et al, Am J Gastroenterol. 2014;109(9):1443–9

In Crohn’s disease patients with enterocutaneous fistula, anti-TNF-antibody therapy may be effective in up to one third of patients, especially in the absence of stenosis and complex fistula.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28272

 

 

 

 

Liver
Biliary Tracts

 

 

Text:

Mandorfer M et al, Gastroenterology. 2014;146(7):1680–90

Patients suffering from cirrhosis and spontaneous bacterial peritonitis should not receive non-selective betablockers.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28273

 

Text:

Zhang H et al, Hepatology. 2014;60(2):468–76

Telbivudine and lamivudine use in late pregnancy for highly viremic mothers is equally well tolerated and effective in reducing mother-to-child transmission.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28274

 

 

Text:

Wu CY et al, Gastroenterology. 2014;147(1):143–51

In patients with chronic hepatitis B infection nucleoside analogue therapy is associated with a reduced risk of hepatocellular carcinoma.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28275

 

 

Oesophagus

Stomach

Duodenum

 

 

Text:

Li WQ et al, J Natl Cancer Inst. 2014;106(7):dju0116

Helicobacter pylori treatment can benefit older patients and those with advanced baseline histopathology, and benefits are present even with post-treatment infection, leading to a reduced risk of gastric cancer.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28276

 

Text:

Asher Wolf W et al, Clin Gastroenterol Hepatol. 2014;12(8):1272–9

Dietary elimination is a successful treatment modality for adults with eosinophilic esophagitis.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28277

 

 

Text:

Ko HM et al, Am J Gastroenterol. 2014;109(8):1277–85

Eosinophilic gastritis in children is highly responsive to dietary restriction therapies, implicating an allergic etiology.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28278

 

Pancreas

 

 

Text:

Munigala S et al, Clin Gastroenterol Hepatol. 2014;12(7):1143–50

Pancreatic adenocarcinoma must be routinely considered as a potential etiology of acute pancreatitis in patients older than 40 years of age.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20367#c28279

Current Falk literature:

 

NEW

The microbiota and intestinal diseases

Authors: B.J. Campbell, J.M. Rhodes

(38 pages)

S19e

 

Picture:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/Titelblatt/S19e_1-2-15.jpg

 

PDF:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/PDF/S19e_1-2-15.pdf

 

 

 

 

Order by email (Please replace text by your email address):

 

mailto:text?subject=FGI%23%2F2015:%20Ordering%20of%20brochure%20S19e&body=Please%20send%20the%20brochure%20to%20the%20following%20address:%0A%0A